Angiogenesis, the sprouting of capillaries from pre-existing vessels, is an essential event in many physiologic processes such as reproduction, development and wound healing. Angiogenesis inhibition has become a potential anti-tumor treatment strategy, as avascular tumors would be expected to be incapable of growth and have little metastatic potential. However, tumor regression in pre-clinical models in response to angiogenesis inhibitors is variable, depending on a host of factors, including the biological characteristics of the specific tumor, pharmacodynamic and pharmacokinetic responses, and the type of model system used. Since complete tumor regressions are rare in these model systems, it appears inhibition of angiogenesis alone may be insufficient for tumor remission. Therefore, combining angiogenesis inhibitors with other chemotherapeutic agents may have greater efficacy at tumor inhibition. MSI-1256F inhibits growth of solid tumors by inhibiting the development of a blood supply to the tumor without direct cytotoxicity to tumor cells. This effect appears to be mediated by the blockade of the stimulation of endothelial cells by any of a multiple of mitogens, apparently by modulation of endothelial cell pH, without obvious effect on quiescent endothelial cells or alteration of VEGF production by tumor cells. Therefore, MSI-1256F for injection is considered well suited for targeted therapy of tumors and other diseases characterized by neovascularization. This Phase IIA clinical trial is being performed to determine the safety and response rates of MSI-1256F for injection as a continuous intravenous infusion in combination with carboplatin and paclitaxel in patients with Stage IIIB (pleural effusion) and Stage IV non-small cell lung cancer.

National Institute of Health (NIH)
National Center for Research Resources (NCRR)
General Clinical Research Centers Program (M01)
Project #
Application #
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Wisconsin Madison
United States
Zip Code
Burgess-Hull, Albert J; Roberts, Linda J; Piper, Megan E et al. (2018) The social networks of smokers attempting to quit: An empirically derived and validated classification. Psychol Addict Behav 32:64-75
Kelly, Elizabeth A; Esnault, Stephane; Liu, Lin Ying et al. (2017) Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma. Am J Respir Crit Care Med 196:1385-1395
Shen, Zhong-Jian; Hu, Jie; Kashi, Venkatesh P et al. (2017) Epstein-Barr Virus-induced Gene 2 Mediates Allergen-induced Leukocyte Migration into Airways. Am J Respir Crit Care Med 195:1576-1585
Anderson, Halie M; Lemanske Jr, Robert F; Evans, Michael D et al. (2017) Assessment of wheezing frequency and viral etiology on childhood and adolescent asthma risk. J Allergy Clin Immunol 139:692-694
Gomez, Jose L; Yan, Xiting; Holm, Carole T et al. (2017) Characterisation of asthma subgroups associated with circulating YKL-40 levels. Eur Respir J 50:
Kelly, Elizabeth A; Esnault, Stephane; Johnson, Sean H et al. (2016) Human eosinophil activin A synthesis and mRNA stabilization are induced by the combination of IL-3 plus TNF. Immunol Cell Biol 94:701-8
Bray, Bethany C; Smith, Rachel A; Piper, Megan E et al. (2016) Transitions in Smokers' Social Networks After Quit Attempts: A Latent Transition Analysis. Nicotine Tob Res 18:2243-2251
Dougherty, Ryan J; Ellingson, Laura D; Schultz, Stephanie A et al. (2016) Meeting physical activity recommendations may be protective against temporal lobe atrophy in older adults at risk for Alzheimer's disease. Alzheimers Dement (Amst) 4:14-7
Johansson, Mats W; Evans, Michael D; Crisafi, Gina M et al. (2016) Serum periostin is associated with type 2 immunity in severe asthma. J Allergy Clin Immunol 137:1904-1907.e2
Lee, Yong Gyu; Jeong, Jong Jin; Nyenhuis, Sharmilee et al. (2015) Recruited alveolar macrophages, in response to airway epithelial-derived monocyte chemoattractant protein 1/CCl2, regulate airway inflammation and remodeling in allergic asthma. Am J Respir Cell Mol Biol 52:772-84

Showing the most recent 10 out of 459 publications